Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Trounced the Market on Thursday

By Eric Volkman – Sep 2, 2021 at 6:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.

What happened

Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna (MRNA 3.15%) well outpaced the S&P 500 index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.

So what

The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).

Specifically, the biotech filed the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.

Child getting a jab from a medical professional.

Image source: Getty Images.

"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies," Moderna quoted its CEO Stéphane Bancel as saying.

Like the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.

Now what

While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Stocks Mentioned

Moderna Stock Quote
Moderna
MRNA
$179.00 (3.15%) $5.46
Pfizer Stock Quote
Pfizer
PFE
$50.24 (1.07%) $0.53
BioNTech Se Stock Quote
BioNTech Se
BNTX
$162.63 (0.62%) $1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.